By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Medicis Pharmaceutical Corp. v. Nycomed US Inc.
1:10-cv-01099; filed December 15, 2010 in the District Court of Delaware
Infringement of U.S. Patent Nos. 6,765,001 ("Compositions and Methods for Enhancing Corticosteroid Delivery," issued July 20, 2004), 7,220,424 (same title, issued May 22, 2007), 7,217,422 (same title, issued May 15, 2007), and 7,794,738 (same title, issued September 14, 2010) following a Paragraph IV certification as part of Nycomed's filing of an ANDA to manufacture a generic version of plaintiff's Vanos® (fluocinonide cream, used to relieve inflammation and itching caused by certain skin conditions that respond to corticosteroids). View the complaint here.
Somaxon Pharmaceuticals Inc. et al. v. Actavis Elizabeth LLC et al.
1:10-cv-01100; filed December 15, 2010 in the District Court of Delaware
• Plaintiffs: Somaxon Pharmaceuticals Inc.; Procom One Inc.
• Defendants: Actavis Elizabeth LLC; Actavis Inc.; Mylan Inc.; Mylan Pharmaceuticals Inc.
Infringement of U.S. Patent No. 6,211,229 ("Treatment of Transient and Short Term Insomnia," issued April 3, 2001) following a Paragraph IV certification as part of defendants' filing of an ANDA to manufacture a generic version of Somaxon's Silenor® (doxepin, used to treat insomnia). View the complaint here.
Warner Chilcott Co. LLC et al. v. Sun Pharma Global Inc.
1:10-cv-01085; filed December 10, 2010 in the District Court of Delaware
Infringement of U.S. Patent No. 7,718,634 ("Method of Treatment Using Bisphosphonic Acid," issued May 18, 2010), licensed to Warner Chilcott, following a Paragraph IV certification as part of Sun's filing of an ANDA to manufacture a generic version of Warner Chilcott's Once-a-Month Actonel® (risedronate sodium, used to treat and prevent postmenopausal osteoporosis). View the complaint here.
Mallinckrodt Inc. v. Watson Laboratories, Inc.-Florida
2:10-cv-06424; filed December 10, 2010 in the District Court of New Jersey
• Plaintiff: Mallinckrodt Inc.
• Defendant: Watson Laboratories, Inc.-Florida; Watson Pharma, Inc.; Watson Pharmaceuticals, Inc.; Alza Corporation
Infringement of U.S. Patent No. 5,914,131 ("Hydromorphone Therapy," issued June 22, 1999) following a Paragraph IV certification as part of Watson's filing of an ANDA to manufacture a generic version of Mallinckrodt's Exalgo® (hydromorphone hydrochloride, used for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time). View the complaint here.
San Francisco Technology Inc. v. Pfizer Inc.
3:10-cv-05597; filed December 9, 2010 in the Northern District of California
False marking based on Pfizer's marking of its Advil Ibuprofen Caplets with U.S. Patent No. 5,087,454 ("Ibuprofen Tablet," issued February 11, 1992), which is expired. View the complaint here.
Shionogi Pharma Inc. et al. v. Mylan Inc. et al.
1:10-cv-01077; filed December 9, 2010 in the District Court of Delaware
• Plaintiffs: Shionogi Pharma Inc.; CIMA Labs Inc.
• Defendants: Mylan Inc.; Mylan Pharmaceuticals Inc.
Infringement of U.S. Patent No. 6,740,341 ("Taste Masking Rapid Release Coating System," issued May 25, 2004), licensed to Shionogi Pharma, following a Paragraph IV certification as part of Mylan's filing of an ANDA to manufacture a generic version of Shionogi's Orapred ODT® (prednisolone sodium phosphate orally disintegrating tablets, used for the control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with asthma or asthma caused by respiratory disorders). View the complaint here.
Comments